20-Hydroxyeicosatetraenoic acid is an endothelium-dependent vasoconstrictor in rabbit arteries

https://doi.org/10.1016/0014-2999(93)90812-VGet rights and content

Abstract

Recently we have demonstrated that 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) constricts rat aortic rings and that this effect is cyclooxygenase- and endothelium-dependent. Incubation of 20-HETE with ram seminal vesicles, a rich source of cyclooxygenase, led to the identification of vasoconstrictor metabolites, the 20-hydroxy-endoperoxides. In the present study, we demonstrated differences in the potency of 20-HETE to constrict several arteries. In all blood vessels tested, the 20-HETE contractile effect was cyclooxygenase- and endothelium-dependent. Differences in contractile potency of 20-HETE varied according to the blood vessels; potency being higher in more muscular arteries than elastic ones. Furthermore, 20-HETE was more potent in eliciting vasoconstriction than its precursor, arachiddonic acid. We also provide evidence for the generation of 20-hydroxy-endoperoxides from 20-HETE by the endothelial cyclooxygenase. 20-HETE is a major arachidonate metabolite formed by the cytochrome P450 monooxygenases in rat, human and rabbit kidneys. In addition, blood cells such as leukocytes have the ability to produce 20-HETE, suggesting its presence in the circulation. Furthermore, 20-HETE has been shown to inhibit platelet aggregation. Thus, the ability of 20-HETE to modulate vascular tone and platelet function implicates a role for this compound in the regulation of hemostasis.

References (30)

  • D.L. DeWitt et al.

    Concentration of prostaglandin endoperoxide synthase and prostaglandin I2 synthase in the endothelium and smooth muscle of bovine aorta

    J. Clin. Invest.

    (1983)
  • B. Escalante et al.

    Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase

    J. Pharmacol. Exp. Ther.

    (1989)
  • B. Escalante et al.

    Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle

    Science

    (1991)
  • M.E. Gerritsen et al.

    Sites of prostaglandin synthesis in the bovine heart and isolated bovine coronary microvessels

    Circ. Res.

    (1981)
  • D.R. Harder et al.
  • Cited by (66)

    • 20-HETE in the regulation of vascular and cardiac function

      2018, Pharmacology and Therapeutics
      Citation Excerpt :

      The link between 20-HETE and hypertension was originally documented in studies indicating that depletion and inhibition of CYP4A reduced blood pressure in the SHR (DaSilva et al., 1994; Escalante, Sacerdoti, Davidian, Schwartzman, & McGiff, 1991; Sacerdoti et al., 1989). These and other studies (Su, Kaushal, & Kroetz, 1998; Xu et al., 2002), together with reports that 20-HETE is a vasoconstrictor (Escalante et al., 1993; Laniado-Schwartzman, Falck, Yadagiri, & Escalante, 1989; Ma et al., 1993), suggested that increased 20-HETE synthesis and/or actions contributed to increased blood pressure in SHR and other experimental models of hypertension (Alonso-Galicia, Maier, Greene, Cowley Jr., & Roman, 2002; Moreno, Maier, Hoagland, Yu, & Roman, 2001; Muthalif et al., 2000; Muthalif et al., 2000)(30-33). Other studies substantiated the notion that 20-HETE contributes to the development of hypertension by demonstrating that: (i) the synthesis of and vascular reactivity to 20-HETE are significantly higher in the SHR than in normotensive rats (Imig et al., 1993; F. Zhang et al., 2001), (ii) inhibition of vascular 20-HETE synthesis by CYP4A2 antisense oligonucleotides decreases blood pressure (M. H. Wang et al., 1998; M. H. Wang et al., 2001), (iii) vascular-selective transduction of CYP4A2 cDNA increases vascular 20-HETE synthesis and produces hypertension in SD rats (Inoue, Sodhi, et al., 2009; J. S. Wang et al., 2006), and (iv) administration of a 20-HETE analog prevents the fall in blood pressure in LPS-induced endotoxic shock in rats (Tunctan et al., 2008).

    • Why and How Drugs Fail

      2017, Innovative Approaches in Drug Discovery: Ethnopharmacology, Systems Biology and Holistic Targeting
    • NS-398 reverses hypotension in endotoxemic rats: Contribution of eicosanoids, NO, and peroxynitrite

      2013, Prostaglandins and Other Lipid Mediators
      Citation Excerpt :

      20-HETE is an ω-hydroxylation product of arachidonic acid that is produced by cytochrome P450 (CYP) enzymes, mainly by the CYP4A and CYP4F isoforms in the kidney, heart, liver, brain, lung, and the vasculature [6–8]. In the vasculature, 20-HETE causes vasoconstriction in several vascular beds, including renal, cerebral, aortic, mesenteric, and coronary arteries [9–13]. 20-HETE activates protein kinase C [14–17], MAPK [18–20], Raf/mitogen-activated protein kinase kinase (MEK)/ERK [21], and Rho-kinase [10] pathways, which all contribute to the regulation of vascular tone.

    • 5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: Contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKKβ/IκB-α/NF-κB pathway, and proinflammatory cytokine formation

      2013, Prostaglandins and Other Lipid Mediators
      Citation Excerpt :

      20-hydroxyeicosatetraenoic acid (20-HETE) is an ω-hydroxylation product of arachidonic acid (AA) that is produced by cytochrome P450 (CYP) enzymes, mainly by the CYP4A and CYP4F isoforms in the kidney, heart, liver, brain, lung, and vasculature [1–4]. In the vasculature, 20-HETE causes vasoconstriction in several vascular beds, including renal, cerebral, aortic, mesenteric, and coronary arteries [5–9]. Activation of protein kinases, such as mitogen-activated protein kinase (MAPK), MAPK kinase (MEK), and extracellular signal-regulated kinase (ERK) which contribute to the regulation of vascular tone, has been shown to mediate to the vasoconstrictor effect of 20-HETE [10–13].

    View all citing articles on Scopus
    View full text